Showing 37 to 48 of 151 results
34 Dead in Telangana Pharmaceutical Factory Fire
A massive fire at a Sigachi Industries pharmaceutical factory in Telangana, India, on Monday, killed at least 34 people and injured many more. The blast, caused by pressure buildup in a spray dryer, resulted in a complete building collapse, trapping numerous workers, many of whom were migrants from ...
34 Dead in Telangana Pharmaceutical Factory Fire
A massive fire at a Sigachi Industries pharmaceutical factory in Telangana, India, on Monday, killed at least 34 people and injured many more. The blast, caused by pressure buildup in a spray dryer, resulted in a complete building collapse, trapping numerous workers, many of whom were migrants from ...
Progress
24% Bias Score
Illegal Laennec Importation Leads to Death, Conviction of Smuggling Ring
Two young Russians were hospitalized after receiving intravenous injections of illegally imported Japanese immunomodulator Laennec; a woman died, leading to the arrest and conviction of a smuggling ring of seven members under Article 238.1 part 2 'a' of the Russian Criminal Code for trafficking coun...
Illegal Laennec Importation Leads to Death, Conviction of Smuggling Ring
Two young Russians were hospitalized after receiving intravenous injections of illegally imported Japanese immunomodulator Laennec; a woman died, leading to the arrest and conviction of a smuggling ring of seven members under Article 238.1 part 2 'a' of the Russian Criminal Code for trafficking coun...
Progress
52% Bias Score
Mexico to Incentivize Pharmaceutical Investment to Combat Medicine Shortages
Mexico City's mayor announced a decree to incentivize international pharmaceutical investment in Mexican medicine production to combat shortages and high import costs, prioritizing companies investing in Mexico for future bids and leveraging the state-owned Birmex.
Mexico to Incentivize Pharmaceutical Investment to Combat Medicine Shortages
Mexico City's mayor announced a decree to incentivize international pharmaceutical investment in Mexican medicine production to combat shortages and high import costs, prioritizing companies investing in Mexico for future bids and leveraging the state-owned Birmex.
Progress
48% Bias Score
EU Deadlocked on Pharmaceutical Data Protection Reform
Poland's attempt to shorten pharmaceutical data protection in the EU to seven years, supported by a dozen smaller countries, failed due to opposition from larger countries prioritizing eight years to boost competitiveness, creating a deadlock that affects patient access to affordable medicines.
EU Deadlocked on Pharmaceutical Data Protection Reform
Poland's attempt to shorten pharmaceutical data protection in the EU to seven years, supported by a dozen smaller countries, failed due to opposition from larger countries prioritizing eight years to boost competitiveness, creating a deadlock that affects patient access to affordable medicines.
Progress
44% Bias Score
German Chemical Industry Rebounds in Q1, but Future Growth Uncertain
Germany's chemical and pharmaceutical industry rebounded strongly in Q1 2020, with a 4.4% revenue increase to €54.8 billion, driven by increased production across various sectors, although future growth faces uncertainties due to US trade policies and competition from China.
German Chemical Industry Rebounds in Q1, but Future Growth Uncertain
Germany's chemical and pharmaceutical industry rebounded strongly in Q1 2020, with a 4.4% revenue increase to €54.8 billion, driven by increased production across various sectors, although future growth faces uncertainties due to US trade policies and competition from China.
Progress
36% Bias Score
WeightWatchers Files for Bankruptcy, Pivots to Telehealth
WeightWatchers, facing declining revenue and an aging customer base, filed for Chapter 11 bankruptcy on Tuesday to eliminate \$1.15 billion in debt, planning to focus on its telehealth division, WeightWatchers Clinic, which saw a 57% revenue increase in the last year, and expects to exit bankruptcy ...
WeightWatchers Files for Bankruptcy, Pivots to Telehealth
WeightWatchers, facing declining revenue and an aging customer base, filed for Chapter 11 bankruptcy on Tuesday to eliminate \$1.15 billion in debt, planning to focus on its telehealth division, WeightWatchers Clinic, which saw a 57% revenue increase in the last year, and expects to exit bankruptcy ...
Progress
32% Bias Score
Grifols Reports Record Revenue, Plans Dividend Resumption
Grifols, a Spanish pharmaceutical company, reported record 2024 revenue of €7.2 billion, exceeding expectations, and plans to resume dividend payments in 2025 while focusing on debt reduction; the company also appointed its first female president, Anne-Catherine Berner.
Grifols Reports Record Revenue, Plans Dividend Resumption
Grifols, a Spanish pharmaceutical company, reported record 2024 revenue of €7.2 billion, exceeding expectations, and plans to resume dividend payments in 2025 while focusing on debt reduction; the company also appointed its first female president, Anne-Catherine Berner.
Progress
44% Bias Score
Sanofi Acquires Blueprint Medicines for $9.1 Billion to Expand Rare Disease Portfolio
Sanofi is acquiring Blueprint Medicines Corporation for $9.1 billion, gaining access to Ayvakit/Ayvakyt, the only approved treatment for systemic mastocytosis, a rare disease, to strengthen its immunology portfolio and further its global leadership in this area.
Sanofi Acquires Blueprint Medicines for $9.1 Billion to Expand Rare Disease Portfolio
Sanofi is acquiring Blueprint Medicines Corporation for $9.1 billion, gaining access to Ayvakit/Ayvakyt, the only approved treatment for systemic mastocytosis, a rare disease, to strengthen its immunology portfolio and further its global leadership in this area.
Progress
44% Bias Score
French Firm Aqemia Speeds Cancer Drug Development with AI and Physics
Aqemia, a French firm founded in 2019, uses AI and physics to accelerate drug molecule creation for head, neck, and thorax cancers; collaborating with Sanofi, Servier, and Johnson & Johnson, it aims for faster, more cost-effective drug development.
French Firm Aqemia Speeds Cancer Drug Development with AI and Physics
Aqemia, a French firm founded in 2019, uses AI and physics to accelerate drug molecule creation for head, neck, and thorax cancers; collaborating with Sanofi, Servier, and Johnson & Johnson, it aims for faster, more cost-effective drug development.
Progress
44% Bias Score
High US Brand-Name Drug Prices: Monopoly Pricing and Market Segregation
American consumers pay three times more for brand-name drugs than the OECD average due to drug company monopoly pricing and market segregation, despite the high development costs and risky nature of pharmaceutical innovation, which leads to unmet needs among lower-income patients.
High US Brand-Name Drug Prices: Monopoly Pricing and Market Segregation
American consumers pay three times more for brand-name drugs than the OECD average due to drug company monopoly pricing and market segregation, despite the high development costs and risky nature of pharmaceutical innovation, which leads to unmet needs among lower-income patients.
Progress
48% Bias Score
Trump Threatens Tariffs to Slash US Drug Prices
President Trump signed a decree on July 2024, threatening trade barriers against foreign pharmaceutical companies unless they lower US drug prices by up to 90% within 30 days; this follows a study showing US drug prices are up to 40% higher than in Europe, with examples like Eliquis costing $606 in ...
Trump Threatens Tariffs to Slash US Drug Prices
President Trump signed a decree on July 2024, threatening trade barriers against foreign pharmaceutical companies unless they lower US drug prices by up to 90% within 30 days; this follows a study showing US drug prices are up to 40% higher than in Europe, with examples like Eliquis costing $606 in ...
Progress
52% Bias Score
CVS Drops Eli Lilly's Zepbound from Preferred Formulary
CVS Health will remove Eli Lilly's weight-loss drug Zepbound from its preferred formulary starting July 1, 2025, prioritizing Novo Nordisk's Wegovy; this impacts 90 million CVS Caremark members and highlights the power of PBMs in shaping drug access and affordability.
CVS Drops Eli Lilly's Zepbound from Preferred Formulary
CVS Health will remove Eli Lilly's weight-loss drug Zepbound from its preferred formulary starting July 1, 2025, prioritizing Novo Nordisk's Wegovy; this impacts 90 million CVS Caremark members and highlights the power of PBMs in shaping drug access and affordability.
Progress
36% Bias Score
Showing 37 to 48 of 151 results